Sisi Zheng, M.D. Titles and Appointments Assistant Professor Schools Medical School Departments Pediatrics You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Sisi Zheng, M.D., is an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center and a member of the Division of Pediatric Hematology and Oncology. She joined the faculty at UT Southwestern in 2021. Dr. Zheng received her bachelor’s degree in molecular biology at the University of Pennsylvania. She then earned her medical degree at Weill Cornell Medical College and subsequently completed her pediatric residency and fellowship training in pediatric hematology-oncology at the Children’s Hospital of Philadelphia. During her fellowship, her research led to the characterization of aberrant splice isoforms that are important to drug resistance against CD22-based immunotherapies. Dr. Zheng’s laboratory research focuses on understanding how inflammation in the bone marrow environment can facilitate the outgrowth of clonally mutated hematopoietic stem cells (HSCs) and contribute to the early development of myeloid leukemias. Dr. Zheng’s clinical interest is in the care of patients in need of bone marrow transplants for malignant and non-malignant diseases. Dr. Zheng is a member of the American Academy of Pediatrics, Children’s Oncology Group, American Society of Hematology, and American Association of Cancer Research. Education Medical Education Weill Cornell Medicine (2014) Residency Children's Hospital of Philadelphia (2017), Pediatrics Fellowship Children's Hospital of Philadelphia (2020), Pediatric Hematology/Oncology Research Interest Bone marrow environment Clonal hematopoiesis Immunology and Host defenses Leukemia Retrotransposons Publications Featured Publications Co-option of retrotransposons promotes antibody diversification. Lauring MC, Yang M, Sarode A, Wang J, Ni Z, Froehlich KA, Zhang W, Wahed S, Zheng S, Goff SP, Wang J, Basu U, Cell 2026 Aug LINE-1 Locus Transcription Nucleates Oncogenic Chromatin Architecture. Lee M, Zhang Y, Lim JYS, Dai T, Ye J, Cervantes MB, Sondhi V, Zheng S, Kim YJ, Chen B, DeBerardinis RJ, Xu J, Cancer Discov 2026 Jan Alternative splicing of its 5' UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres-Diz M, Xu F, Zankharia U, Zhang Y, Soldan SS, Zheng S, Falkenstein CD, Loftus JP, Yang SY, Asnani M, King Sainos P, Pillai V, Chong ER, Li M, Tasian SK, Barash Y, Lieberman PM, Ruella M, Schuster SJ, Thomas-Tikhonenko A, Blood 2023 Sep Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. Zheng S, Gillespie E, Naqvi AS, Hayer KE, Ang Z, Torres-Diz M, Quesnel-Vallières M, Hottman DA, Bagashev A, Chukinas J, Schmidt C, Asnani M, Shraim R, Taylor DM, Rheingold SR, O'Brien MM, Singh N, Lynch KW, Ruella M, Barash Y, Tasian SK, Thomas-Tikhonenko A, Blood Cancer Discov 2021 Nov Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, Ibrahim F, Maragkakis M, Gazzara MR, Black KL, Bagashev A, Taylor D, Mourelatos Z, Grupp SA, Barrett D, Maris JM, Sotillo E, Barash Y, Thomas-Tikhonenko A, Leukemia 2020 Apr 34 4 1202-1207 Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors. Zheng S, Asnani M, Thomas-Tikhonenko A, Cancer J 2019 25 3 217-222 Results 1-6 of 6 1
